Session » (0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0677

Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan

9:00AM-11:00AM: Abstract Number: 0687

Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain

9:00AM-11:00AM: Abstract Number: 0682

Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients

9:00AM-11:00AM: Abstract Number: 0678

Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 0688

Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)

9:00AM-11:00AM: Abstract Number: 0685

Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 0674

Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 0675

Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond

9:00AM-11:00AM: Abstract Number: 0679

Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)

9:00AM-11:00AM: Abstract Number: 0676

Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center

9:00AM-11:00AM: Abstract Number: 0681

Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0683

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0684

Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0673

Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials

9:00AM-11:00AM: Abstract Number: 0680

Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study

9:00AM-11:00AM: Abstract Number: 0686

Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0690

Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy

9:00AM-11:00AM: Abstract Number: 0689

Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2

« View all sessions from this meeting